[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BPharmCatalyst Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::56121651.png) BioPharmCatalyst [@BPharmCatalyst](/creator/twitter/BPharmCatalyst) on x 29.9K followers
Created: 2025-07-22 20:51:45 UTC

$ABVX shares are halted following results that its 50mg obefazimod achieved XXXX% pooled placebo-adjusted clinical remission at X weeks in Phase X ABTECT induction trials for moderate-to-severe UC, meeting all key secondary endpoints with favorable safety. Maintenance data is due 2Q 2026, ahead of planned NDA/MAA submissions in 2H 2026. The company also delayed 1H 2025 financial results from August XX to September 8, 2025. Preliminary cash and cash equivalents as of June 30, 2025, were approximately $XXXX million (unaudited).

See More Biotech Updates👇


$IOVA $REPL $PMN $QNTM $STRO $AMIX $ABVX

![](https://pbs.twimg.com/media/GwfWwoGWkAAd7rE.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1947761507086864534/c:line.svg)

**Related Topics**
[stocks](/topic/stocks)
[$abvx](/topic/$abvx)

[Post Link](https://x.com/BPharmCatalyst/status/1947761507086864534)